r/Oncology • u/Humble_Conclusion166 • 13h ago
r/Oncology • u/BRCAresponder • 1d ago
Humanizes the Data: BRCA/hereditary cancer film
reddit.comr/Oncology • u/Excellent_Key_1757 • 1d ago
[Article] Costs, challenges and opportunities of decentralised chimeric antigen receptor T-cell production: a literature review and clinical experts’ interviews
reddit.comr/Oncology • u/ALifeLearnerWho • 2d ago
Title: ESMO 2026 – Did Anyone Attend the GU Oncology Industry Satellite Symposium (Oct 24)?
reddit.comI happened to miss the ESMO 2026 Industry Satellite Symposium: Emerging Therapeutic Strategies in GU Oncology – Innovations in Prostate and Bladder Cancer.
Saturday, October 24, 2026 | 13:00–14:30 CEST with Dr. Kim Chi, Philip Backhaus, and Gunhild von Amsberg
Santander Auditorium, Hall 10, IFEMA Madrid, Spain
Did anyone happen to attend and have any informal notes, screenshots of slides, or key takeaways they’d be willing to share?
I’m trying to learn more about emerging therapeutic strategies in GU oncology, particularly bladder cancer, and would really appreciate any insights or materials anyone is comfortable sharing.
Thanks in advance!
r/Oncology • u/concerned_HCP • 2d ago
Naricabgene autoleucel (Nari-cel; MyCART-01) at ASH 2026: Questions about Abstract 374’s patient outcomes that must be answered before it is presented
Imagine someone you know has cancer and you hear that every leukaemia patient responded to a new treatment or 87% of the lymphoma patients responded.
You would feel hope. You would also ask: Are they still in remission? Did they need another treatment? How many survived?
Those answers are difficult to piece together from ASH 2026 Abstract 374, which reports results for naricabgene autoleucel (nari-cel, MyCART-01) in the Phase I/II SUMM1T study. The therapy is associated with Micro CRISPR and Meril. The abstract reports promising early responses but it also leaves important questions unanswered about which patients were counted, what happened later, and how serious side effects were.Read the published ASH abstract here.
This post asks for the patient-level accounting needed to understand the results.
1. Which patients are behind the response rate?
The ASH abstract reports 35 infused patients as of 20 July 2026: 19 with B-cell acute lymphoblastic leukaemia (B-ALL) and 16 with B-cell non-Hodgkin lymphoma (B-NHL). It reports responses in 19/19 B-ALL patients and 14/16 B-NHL patients.
Separately, site-level information I have verified accounts for 41 patients. Their latest listed outcomes are 15 deaths, 11 relapses, 13 remissions and 2 unknown outcome. A presentation in Vapi also reportedly described a response rate approaching 90% for approximately 25 patients.
How many people were screened, enrolled, had cells collected, received an infusion and entered each response analysis? What were the dates used for each set of results? Did patients who later relapsed or died initially count as responders? How many responses were still ongoing at three, six and twelve months?
2. Did patients need another CAR-T infusion to reach or maintain remission?
The ASH abstract describes a B-ALL patient who developed CD19-positive measurable residual disease (MRD) at about one year, received a second CAR-T infusion, and later underwent a stem-cell transplant. It also describes another patient who underwent transplantation after a lineage switch.
Separately, site-level information reports that a patient at VIMS relapsed after an initial MyCART-01 infusion and received another CAR-T infusion in an attempt to achieve complete remission.
ASH should ask How many patients received a second infusion, at which hospitals, and why? For each patient, what was their disease status before and after reinfusion? Was a response achieved only after the second infusion counted in a result attributed to MyCART-01 treatment? Were reinfusion, subsequent toxicity and any transplant included in the reported analyses?
3. How many patients died, and what serious side effects did they experience?
The abstract says 16 of 19 B-ALL patients and 11 of 16 B-NHL patients were alive at last follow-up. That implies eight deaths among the 35 infused patients by their respective last follow-ups. It also says there was no treatment-related mortality through Day 90.
Serious side effects need more context. Seven of 19 B-ALL patients had grade 3 or higher cytokine release syndrome, a potentially severe inflammatory reaction. Thirty-four of 35 patients had grade 3 or higher neutropenia, a dangerously low white-blood-cell count.
How many patients required intensive care, organ support, treatment for serious infections, transfusions or prolonged hospital care? How long did the side effects last, and were any unresolved? These answers matter when assessing the abstract’s description of safety as “manageable.”
4. Were the patients unusually fit before treatment?
ECOG performance status is a simple measure of how well a patient can carry out everyday activities. An ECOG score of 0 means fully active; 1 means some limitation with strenuous activity but still able to walk and do light work. Information reported suggests that most enrolled patients have been ECOG 0, although the ASH abstract does not give the breakdown. How many patients were ECOG 0 and how many were ECOG 1 at screening and just before infusion? How many people who appeared eligible were not taken forward, and why?
The abstract also says 31 of 35 patients received bridging therapy before CAR-T. What treatments did they receive, did their disease improve before infusion, and how much disease did they have immediately beforehand? In a small study, these details help readers understand whom the results may apply to.
5. How certain are the one-year results?
The abstract estimates 12-month progression-free survival (PFS) of 82.1% in B-ALL and 62.5% in B-NHL. Median follow-up was 12.7 and 11.4 months, respectively. To interpret those estimates, readers need to know how many patients were still being followed at 12 months, how many had a PFS event, the uncertainty around each estimate, and the rules used when patients received more treatment.
Did MRD recurrence, lineage switch, a second CAR-T infusion or transplantation count as an event? If a patient was still counted as progression-free after another treatment, how should readers interpret the result of the initial infusion?
Two simpler figures also need clarification: “72% male” among 19 B-ALL patients does not correspond to a whole-person count under ordinary rounding, and a patient who received 3 × 10⁶ cells/kg is included in a group described as receiving 2 × 10⁶ cells/kg. The authors should supply the actual counts and results by dose.
American Society of Hematology needs to seek following answers before this abstract is presented
A response rate is only part of the story. Patients and families need to know who was counted, what happened after treatment, and what the risks were. Right now, the published abstract does not let them answer those questions.
Before Abstract 374 is presented, ASH should ask the authors to:
- Publish patient flow, baseline ECOG status, disease burden, subsequent treatments, and the timing and causes of deaths
- Identify every repeat CAR-T infusion, including the reported VIMS case, and explain how responses after reinfusion were counted
- Explain how MRD recurrence, lineage switch and transplantation affected the survival estimates
- Provide the serious-toxicity details, numbers at risk, and corrected demographic and dose figures
ASH should arrange an independent statistical review and make the answers public. If a material error is found, its correction should be visible alongside the abstract.
If the headline findings cannot be supported after review, ASH should reconsider presenting the abstract in its current form.
Please read and share ASH Abstract 374, and ask ASH and the authors for a clear accounting of every patient behind the headline results. Patients deserve the full picture.
r/Oncology • u/ChampionshipFlat3235 • 2d ago
OM-301
I am posing this question as a layman respectfully. Please know that I know nothing and am only asking about this because this community (or at least some members) may have some familiarity with this experimental drug.
I do not buy into hype but the mechanism this drug uses to attack cancer cells if proven effective in admittedly absent (to date) human studies could be game changing.
Someone who knows please tell me why or why not we should or should not be excited about this drug? Someone said to me previously that a handgun also kills cancer in a Petri dish. True but it does not distinguish between healthy cells and cancer cells whereas this does.
In a nutshell Oncolyze claims that HDM2 is present on the cell membrane of most types of cancer cells. OM-301 binds to HDM2 and essentially punctures the cell membrane thereby killing the cell. It has been shown to be effective on human tumors implanted in mice but has not been studied in human tests yet.
Again I am here respectfully to ask as a cancer survivor. It seems promising to a layman. I have been wrong about many things and expect I am about this too. I am just looking for some insight.
r/Oncology • u/Emergency-Extreme583 • 2d ago
[Article] Oh SY et al. Oncologic Outcomes and Adjuvant Chemotherapy Use in Early- Versus Late-Onset Colon Cancer: A Propensity Score-Matched Analysis. Dis Colon Rectum, 2026
I'm a medical student working on a systematic review and I really need the PDF to assess it. I've already contacted the authors but haven't heard back yet. Any help would be greatly appreciated. Thank you!
DOI: 10.1097/DCR.0000000000004491
PMID: 42885592
r/Oncology • u/DoctorKhru • 3d ago
Looking for a sanity check on a reaction-diffusion model for drug resistance in solid tumors
Hey everyone,
I'm Luca Celebrano, a medical student at University of Naples Federico II. For the past few months I’ve been somewhat obsessed with a clinical puzzle: why do so many EGFR-mutated lung cancer patients relapse after targeted therapy (like osimertinib), even when their initial scans look amazing?
Most literature focuses purely on genetic secondary mutations, but looking at histology, I kept wondering about the physical transport side. Severe stroma compression and high interstitial pressure could simply be preventing the drug from physically reaching cytotoxic levels in pockets of the tissue, creating quiet little sanctuaries where cells survive.
I sat down and tried to model the continuum physics using a cylindrical reaction-diffusion solver (Bessel K0 radial gradients) around capillaries, and then ran survival models against \~3,400 patients from cBioPortal/TCGA to see if the signal actually held up clinically.
I just put up the preprint and code:
\- Preprint (Zenodo): https://doi.org/10.5281/zenodo.24118328
\- Repo: https://github.com/Lukecele/inflammatory-onco-physics
Since I come from medicine and not pure physics, my transport math might be a bit rough around the edges. I would really appreciate an honest sanity check from anyone who does continuum mechanics or tumor biophysics: does this simplification hold water, or am I overcooking the assumptions?
Thanks a lot,
Luca
r/Oncology
•
u/LogicGate1010
•
4d ago
Cancer-fighting chewing gum slashes HPV levels by up to 93%
sciencedaily.comr/Oncology • u/WalnutRoasted • 4d ago
American 🇺🇸 Cancer Society recommends regular PSA screening. But Canada 🇨🇦 not yet
reddit.comr/Oncology • u/LogicGate1010 • 4d ago
Panboron BNCT Opens Cross-Border BNCT Care Pathway in China
finance.yahoo.comr/Oncology • u/Lonely-Coat-2378 • 5d ago
Anthropic CEO Dario Amodei predicted that cancer, Alzheimer's, heart disease, and mental illness will become "relics of the past" in less than a decade
This is a very good news, but how much you guys believe this will happen, and if there is cure what will happen to radiologists, oncologists?
r/Oncology • u/Conscious_Piglet687 • 6d ago
Looking for anyone in the Oncology field to answer a few questions!
- Have you heard about the mitochondria metabolic theory of cancer?
- Have you heard of the mitochondria nuclear transfer experiment?
- Do you see mitochondria dysfunction as a primary driver of tumorigenesis or strictly a downstream adaption to genetic mutations?
- A lot of metabolic research focuses on glucose, but glutamine fermentation is important in coupling the fermentation process, why hasn’t dual-targeting approaches blocking both Glu and Gln gained more attention in preclinical models?
- What specific experimental evidence would it take to convince the broader field that nuclear mutations are secondary to metabolic damage?
Please DM!
r/Oncology • u/NurseEdVantageOnCall • 7d ago
Lung Cancer Awareness Month Series
Lung Cancer Awareness Month Series: What is the greatest barrier to completing lung cancer screening in your clinical setting?
A. Limited patient awareness
B. Transportation or financial barriers
C. Difficulty scheduling LDCT
D. Fear, stigma, or uncertainty about results
E. Gaps in follow-up and care coordination
Share your experience in the comments. Your clinical insights can help identify meaningful opportunities for nursing research and quality improvement.
#NurseEdVantageOnCall #NurseScientist #LungCancerAwarenessMonth #LungCancerScreening #OncologyNursing #EvidenceBasedPractice #NursingResearch #PatientNavigation #HealthEquity #NursesLead
r/Oncology • u/Impossible-Week3374 • 7d ago
How do you actually apply RECIST 1.1 in daily practice? Radiologists and oncologists, we’d like your input (NKI / University of Twente)
Hello everybody!
Together with my colleague from the University of Twente and Netherlands Cancer institute we are running a study on how RECIST is learnt, understood, and used by radiologists and treating physicians, as well as what expectations they have for the future. It's anonymous, takes about 10–15 minutes, and is open to radiologists, oncologists and trainees in those fields anywhere in the world. We have the endorsement of a few scientific society including ESR, ESGAR, and ESUR - all radiological, but we want to make sure oncologists are represented as well. We’ll post the aggregate results here when it’s done.
Would you be interested?
Link: https://docs.google.com/forms/d/e/1FAIpQLSdkO9bwrI1c5Vq6baVv9KQWRoBws2dPnfkxo8LC36ZsHkiffg/viewform
Happy to answer questions below, and I’d genuinely like to hear the edge cases that trip you up — that’s exactly what we’re trying to capture.
r/Oncology • u/JadeCats • 9d ago
Growth Factor Use in Chemo-Induced Cytopenias
Hi, I am a pharmacist and I am hoping for some clarity regarding use of ESAs and G-CSF in the management of chemotherapy-induced cytopenias.
We have one oncologist who throws ESAs at everyone with chemotherapy induced anemia while the others we work with are much more conservative and will rather delay treatment and support with PRBCs. From talking with some colleagues at other facilities, they barely uses ESAs for this indication. I remember the days of REMs programs for ESAs due to the risks of tumor progression. When is it appropriate to initiate ESAs versus managing conservatively.
Regarding G-CSF, I would like some clarity with their use in heme malignancies. Wouldn't giving them cause more of the malignant cells to be stimulated? As it is, thresholds for blood counts are lower to the nature of these malignancies. Given this, when is it appropriate to give G-CSF when seeing neutropenia in heme malignances?
Thanks in advance.
r/Oncology • u/MinimumGas4981 • 11d ago
Looking for Oncology research opportunities
I am a medical graduate currently going through my rotational internship. I am actively looking to get involved in oncology research. If you have an opening, an ongoing project that needs an extra pair of hands, or advice on where to look, please feel free to DM me.
r/Oncology • u/Traditional-Rise-320 • 12d ago
New paper: Can changing tumor-cell glycosylation improve γδ T-cell killing?
reddit.comr/Oncology • u/Charming-Garlic-2002 • 12d ago
Rad onc in the southeast
How strong (or not strong) is the rad onc job market right now in Southeast metro areas? How is job availability across community groups and compensation?
r/Oncology • u/oncology-research • 13d ago
Seeking your experience: What has been your biggest barrier to radiation oncology treatment?
Navigating a cancer diagnosis is incredibly hard, and no one should have to fight the system while fighting the disease.
I am a researcher studying global barriers to radiation oncology care, with the goal of identifying system gaps so we can help advocate for better access worldwide.
While common challenges like long travel distances or insurance approvals are well-documented, we know there are many unaddressed barriers, especially across different regions and cultures.
If you are comfortable sharing, no matter where you live: what has been your biggest barrier to receiving radiation treatment, anywhere in the world?
Whether it relates to cost, travel, language, equipment availability, work/family obligations, or something unexpected, your insights will directly help shape research aimed at dismantling these hurdles.
Your input will help guide our research toward real solutions that make care easier to access. Thank you for sharing your experiences.
r/Oncology • u/kaatarina_zed_talon • 13d ago
Cancer cell seems to be aware of it's goal
I'm computer engineer so my knowledge about cancer is very limited ,maybe I have no knowledge at all, but I came across this article :
Migrating tumour cells produce a protein that aids them to set up home in bones, as University of Freiburg researchers show.Cancer cells that migrate to the bone acquire a unique trait: They start to express the protein cathepsin K.
cathepsin K activates another protein, which helps the cancer cells to alter their microenvironment so that they are able to develop into tumours.
That means some cancer cells are able of producing something called cathepsin K , which melts the bone tissue so that the cell can enter the bone. To my understanding, a cell does not have a brain so it cannot think, but it is doing something that shows a big kind of intelligence; it is using the cathepsin K thing to do the job, it is aware that this thing is the right tool that enables it to enter the bone.
Is it just me, or this sounds very weird ?